RecruitingPhase 2Phase 3NCT06055959

A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

A Multicenter Open-Label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Activity of Zilucoplan in Pediatric Study Participants From 2 to Less Than 18 Years of Age With Acetylcholine Receptor Antibody Positive Generalized Myasthenia Gravis

Sponsor

UCB Biopharma SRL

Enrollment

8 participants

Start Date

Oct 16, 2024

Study Type

INTERVENTIONAL

Conditions

Generalized Myasthenia Gravis

Summary

The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, safety, tolerability, immunogenicity and activity of zilucoplan (ZLP) in pediatric study participants with generalized myasthenia gravis (gMG).

Eligibility

Min Age: 12 YearsMax Age: 17 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Zilucoplan for people with generalized myasthenia gravis. The study is currently recruiting participants at 9 locations. People eligible for this study include aged 12 Years to 17 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGZilucoplan

Zilucoplan will be administered subcutaneously to pediatric study participants.

Locations(9)

Mg0014 50168

Chicago, Illinois, United States

Mg0014 50574

Denton, Texas, United States

Mg0014 40144

Milan, Italy

Mg0014 40774

Katowice, Poland

Mg0014 40218

Warsaw, Poland

Mg0014 20104

Seoul, South Korea

Mg0014 20220

Seoul, South Korea

Mg0014 40735

Glasgow, United Kingdom

Mg0014 40736

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06055959

Related Trials

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

NCT06463587145 locations

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)

NCT069875394 locations

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

NCT0619388922 locations

Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis

NCT0670426911 locations

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

NCT06517758125 locations